Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Peer C Tfelt-Hansen,
Jes Olesen
28
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Receptor Agonist
100%
Migraine Treatment
100%
Potential Treatments
100%
5-hydroxytryptamine
100%
Migraine Attack
100%
Placebo-controlled
100%
Phase II Trial
100%
Placebo
40%
Acute Treatment
30%
Adverse Events
30%
Migraine
10%
Triptans
10%
Linear Association
10%
Patient Preference
10%
Vasodilator
10%
Clinically Significant
10%
Non-vascular
10%
Migraine Pathophysiology
10%
Dose Level
10%
Treatment Principles
10%
High Incidence
10%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Receptor Agonist
100%
Phase II Trials
100%
Migraine
100%
Headache
40%
Randomized Controlled Trial
30%
Adverse Event
30%
Pathophysiology
10%
Triptan Derivative
10%